Identification

Name
Quetiapine
Accession Number
DB01224  (APRD00675)
Type
Small Molecule
Groups
Approved
Description

Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.

Structure
Thumb
Synonyms
  • 2-[2-(4-Dibenzo[b,F][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol
  • Quetiapina
  • Quetiapine
  • Quetiapine fumarate
  • Quetiapine hemifumarate
  • Quetiapinum
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act QuetiapineTablet300 mgOralActavis Pharma Company2008-09-04Not applicableCanada
Act QuetiapineTablet25 mgOralActavis Pharma Company2008-09-04Not applicableCanada
Act QuetiapineTablet200 mgOralActavis Pharma Company2008-09-04Not applicableCanada
Act QuetiapineTablet150 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
Act QuetiapineTablet100 mgOralActavis Pharma Company2008-09-04Not applicableCanada
QuetiapineTablet25 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
QuetiapineTablet300 mgOralSivem Pharmaceuticals Ulc2009-02-26Not applicableCanada
QuetiapineTablet200 mgOralSanis Health Inc2010-07-26Not applicableCanada
QuetiapineTablet150 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
QuetiapineTablet25 mgOralSivem Pharmaceuticals Ulc2009-02-26Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-quetiapineTablet, multilayer, extended release25 mgOralBgp Pharma Ulc2014-06-092015-12-31Canada
Abbott-quetiapineTablet, multilayer, extended release200 mgOralBgp Pharma Ulc2014-06-132015-12-31Canada
Abbott-quetiapineTablet, multilayer, extended release100 mgOralBgp Pharma Ulc2014-06-092015-12-31Canada
Abbott-quetiapineTablet, multilayer, extended release300 mgOralBgp Pharma Ulc2014-06-092015-12-31Canada
Accel-quetiapineTablet150 mgOralAccel Pharma Inc2015-03-032017-01-27Canada
Accel-quetiapineTablet300 mgOralAccel Pharma Inc2015-03-262017-01-27Canada
Accel-quetiapineTablet100 mgOralAccel Pharma Inc2015-03-262017-01-27Canada
Accel-quetiapineTablet200 mgOralAccel Pharma Inc2015-03-262017-01-27Canada
Accel-quetiapineTablet25 mgOralAccel Pharma Inc2015-03-262017-01-27Canada
Ach-quetiapine Fumarate XRTablet, extended release150 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Categories
UNII
BGL0JSY5SI
CAS number
111974-69-7
Weight
Average: 383.507
Monoisotopic: 383.166747749
Chemical Formula
C21H25N3O2S
InChI Key
URKOMYMAXPYINW-UHFFFAOYSA-N
InChI
InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
IUPAC Name
2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol
SMILES
OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12

Pharmacology

Indication

For the treatment of schizophrenia and related psychotic disorders.

Associated Conditions
Pharmacodynamics

Quetiapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Quetiapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), and dopamine type 2 (D2) receptors. Quetiapine is an antagonist at serotonin 5-HT1A and 5HT2, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors. Quetiapine has no significant affinity for cholinergic muscarinic or benzodiazepine receptors. Drowsiness and orthostatic hypotension associated with use of quetiapine may be explained by its antagonism of histamine H1 and adrenergic alpha 1 receptors, respectively. Quetiapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.

Mechanism of action

Quetiapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
AD(2) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
U5-hydroxytryptamine receptor 1B
other/unknown
Human
U5-hydroxytryptamine receptor 1D
other/unknown
Human
U5-hydroxytryptamine receptor 1E
other/unknown
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
U5-hydroxytryptamine receptor 3A
other/unknown
Human
U5-hydroxytryptamine receptor 6
other/unknown
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UD(1B) dopamine receptor
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
UHistamine H1 receptor
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
UAlpha-2A adrenergic receptor
antagonist
Human
UAlpha-2B adrenergic receptor
antagonist
Human
UAlpha-2C adrenergic receptor
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M4
antagonist
Human
UMuscarinic acetylcholine receptor M5
antagonist
Human
Absorption

Rapidly and well absorbed.

Volume of distribution
  • 10±4 L/kg
Protein binding

83%

Metabolism

Hepatic. The major metabolic pathways are sulfoxidation, mediated by cytochrome P450 3A4 (CYP3A4), and oxidation of the terminal alcohol to a carboxylic acid. The major sulfoxide metabolite of quetiapine is inactive. Quetiapine also undergoes hydroxylation of the dibenzothiazepine ring, O-deakylation, N-dealkylation, and phase II conjugation. The 7-hydroxy and 7-hydroxy- N-delakylated metabolites appear to be active, but are present in very low concentrations.

Route of elimination

Elimination of quetiapine is mainly via hepatic metabolism. Following a single oral dose of 14C-quetiapine, less than 1% of the administered dose was excreted as unchanged drug, indicating that quetiapine is highly metabolized. Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.

Half life

6 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include drowsiness and sedation, tachycardia, and hypotension.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Quetiapine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Quetiapine.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Quetiapine.Investigational
2,5-Dimethoxy-4-ethylamphetamineQuetiapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineQuetiapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineQuetiapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineQuetiapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineQuetiapine may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Quetiapine can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Quetiapine.Approved, Investigational
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Quetiapine.Approved, Investigational
AcepromazineQuetiapine may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aceprometazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Quetiapine.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Quetiapine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Adipiplon.Investigational
AdrafinilQuetiapine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineQuetiapine may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Quetiapine.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alaproclate.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quetiapine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Quetiapine.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Quetiapine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Quetiapine.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Quetiapine.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Quetiapine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Quetiapine.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Quetiapine.Approved, Withdrawn
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Quetiapine.Approved
AmibegronQuetiapine may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Quetiapine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Quetiapine.Approved
AmiodaroneThe serum concentration of Quetiapine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideQuetiapine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazQuetiapine may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineQuetiapine may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Quetiapine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amobarbital.Approved, Illicit
AmoxapineQuetiapine may increase the antihypertensive activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amperozide.Experimental
AmphetamineQuetiapine may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Quetiapine.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Quetiapine is combined with Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amyl Nitrite.Approved
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Quetiapine.Approved
AnisodamineQuetiapine may decrease the vasoconstricting activities of Anisodamine.Investigational
ApalutamideThe serum concentration of Quetiapine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Quetiapine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Quetiapine.Approved
AprepitantThe serum concentration of Quetiapine can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Quetiapine is combined with Aranidipine.Approved, Investigational
ArbutamineQuetiapine may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Quetiapine.Approved, Investigational
ArmodafinilThe metabolism of Quetiapine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Quetiapine.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Quetiapine.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Articaine.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Asenapine.Approved
AtazanavirThe serum concentration of Quetiapine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Quetiapine.Approved
AvanafilAvanafil may increase the hypotensive activities of Quetiapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Azaperone.Investigational, Vet Approved
AzelastineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Quetiapine is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Azilsartan medoxomil.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Quetiapine is combined with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Quetiapine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Quetiapine.Investigational
BambuterolQuetiapine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Quetiapine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Quetiapine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Quetiapine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Quetiapine.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Quetiapine.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Quetiapine.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Quetiapine is combined with Bencyclane.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Quetiapine.Approved
BenidipineThe risk or severity of hypotension can be increased when Quetiapine is combined with Benidipine.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Benzocaine.Approved, Investigational
BenzphetamineQuetiapine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Quetiapine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineQuetiapine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Quetiapine.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Quetiapine.Approved, Investigational
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Quetiapine.Approved, Investigational
BevantololQuetiapine may increase the antihypertensive activities of Bevantolol.Approved
BioallethrinThe risk or severity of hypotension can be increased when Quetiapine is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
BitolterolQuetiapine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe serum concentration of Quetiapine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
BosentanThe serum concentration of Quetiapine can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Quetiapine.Approved
BrexpiprazoleQuetiapine may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrigatinibThe serum concentration of Quetiapine can be decreased when it is combined with Brigatinib.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Quetiapine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Quetiapine.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Quetiapine.Investigational, Withdrawn
BufuralolBufuralol may increase the orthostatic hypotensive activities of Quetiapine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Quetiapine.Approved
BunazosinBunazosin may increase the antihypertensive activities of Quetiapine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
BuprenorphineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Quetiapine can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Quetiapine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Quetiapine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quetiapine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Quetiapine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Quetiapine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Quetiapine is combined with Canertinib.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Quetiapine.Approved
CarbamazepineThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Quetiapine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Quetiapine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carbinoxamine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Quetiapine is combined with Carboxyamidotriazole.Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Quetiapine.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carisoprodol.Approved
CaroverineThe risk or severity of hypotension can be increased when Quetiapine is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Quetiapine.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Quetiapine.Experimental
CelecoxibThe metabolism of Quetiapine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Quetiapine.Approved, Investigational
CeritinibThe serum concentration of Quetiapine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Quetiapine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Quetiapine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chloroprocaine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quetiapine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorphenamine.Approved
ChlorphentermineQuetiapine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Quetiapine.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Quetiapine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Quetiapine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Quetiapine.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Quetiapine.Approved, Investigational
CimetidineThe metabolism of Quetiapine can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Quetiapine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Quetiapine is combined with Cinnarizine.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
CirazolineQuetiapine may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Quetiapine.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Quetiapine.Approved
ClarithromycinThe serum concentration of Quetiapine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Quetiapine can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolQuetiapine may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clidinium.Approved
ClobazamThe metabolism of Quetiapine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Quetiapine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Quetiapine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Quetiapine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quetiapine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Quetiapine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Quetiapine.Approved
CobicistatThe serum concentration of Quetiapine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Quetiapine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Quetiapine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Quetiapine.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Quetiapine.Approved
CurcuminThe serum concentration of Quetiapine can be increased when it is combined with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Quetiapine is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quetiapine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Quetiapine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Quetiapine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dantrolene.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dapagliflozin.Approved
DapiprazoleDapiprazole may increase the antihypertensive activities of Quetiapine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Quetiapine.Investigational
DarifenacinThe metabolism of Quetiapine can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Quetiapine is combined with Darodipine.Experimental
DarunavirThe serum concentration of Quetiapine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Quetiapine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Quetiapine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Quetiapine.Approved
DelavirdineThe metabolism of Quetiapine can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Quetiapine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Quetiapine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineQuetiapine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Quetiapine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Quetiapine.Approved, Illicit, Investigational, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Quetiapine.Approved, Investigational
Diethyl etherThe risk or severity of adverse effects can be increased when Quetiapine is combined with Diethyl ether.Experimental
DiethylpropionQuetiapine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Quetiapine can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Quetiapine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dinutuximab.Approved, Investigational
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quetiapine.Approved, Illicit
DipivefrinQuetiapine may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Quetiapine.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Quetiapine.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dixyrazine.Experimental
DL-MethylephedrineQuetiapine may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineQuetiapine may decrease the vasoconstricting activities of Dobutamine.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Quetiapine.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Quetiapine.Approved, Investigational, Vet Approved
DopexamineQuetiapine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Quetiapine can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Quetiapine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Quetiapine.Approved
DoxepinQuetiapine may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineQuetiapine may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxycyclineThe metabolism of Quetiapine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Quetiapine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Drotebanol.Experimental, Illicit
DroxidopaQuetiapine may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Quetiapine.Approved, Investigational
DuloxetineQuetiapine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ecopipam.Investigational
EfavirenzThe metabolism of Quetiapine can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Quetiapine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Quetiapine.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Quetiapine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Quetiapine.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Enflurane.Approved, Investigational, Vet Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Quetiapine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Quetiapine can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Quetiapine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Quetiapine is combined with Eperisone.Approved, Investigational
EphedraQuetiapine may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineQuetiapine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineQuetiapine may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineQuetiapine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Quetiapine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Quetiapine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Quetiapine.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Quetiapine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Quetiapine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Quetiapine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Quetiapine.Experimental
EscitalopramThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Quetiapine.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Quetiapine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
EsomeprazoleThe metabolism of Quetiapine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Quetiapine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Quetiapine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Quetiapine.Approved, Investigational
EtafedrineQuetiapine may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etifoxine.Investigational, Withdrawn
EtilefrineQuetiapine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Quetiapine can be decreased when combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Quetiapine.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Quetiapine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Quetiapine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Quetiapine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Quetiapine is combined with Fendiline.Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Quetiapine.Approved
FenoterolQuetiapine may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quetiapine.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quetiapine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fexofenadine.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Quetiapine.Approved, Investigational
FingolimodFingolimod may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Quetiapine is combined with Fish oil.Approved, Nutraceutical
FlecainideFlecainide may increase the QTc-prolonging activities of Quetiapine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Quetiapine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Quetiapine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Quetiapine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Quetiapine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Quetiapine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Quetiapine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
FosamprenavirThe metabolism of Quetiapine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Quetiapine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Quetiapine.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Quetiapine.Approved
FosphenytoinThe serum concentration of Quetiapine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Quetiapine.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Quetiapine.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Quetiapine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Quetiapine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Quetiapine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Gabapentin Enacarbil.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
GalantamineGalantamine may increase the QTc-prolonging activities of Quetiapine.Approved
GallopamilThe risk or severity of hypotension can be increased when Quetiapine is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Quetiapine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Quetiapine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
GepefrineQuetiapine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Quetiapine.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Quetiapine.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Quetiapine.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Quetiapine.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Quetiapine.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Glutethimide.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Quetiapine.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Quetiapine.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
GuanabenzQuetiapine may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Quetiapine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Quetiapine.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Quetiapine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hexobarbital.Approved
HexoprenalineQuetiapine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineQuetiapine may decrease the vasoconstricting activities of Higenamine.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Quetiapine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Quetiapine.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Quetiapine.Approved, Vet Approved
HydrocodoneQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Quetiapine.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quetiapine.Approved, Illicit
HydroxyamphetamineQuetiapine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Quetiapine.Approved
IdelalisibThe serum concentration of Quetiapine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Quetiapine.Approved, Investigational
ImatinibThe metabolism of Quetiapine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Quetiapine.Investigational
ImipramineQuetiapine may increase the antihypertensive activities of Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Quetiapine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Quetiapine.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Quetiapine.Withdrawn
IndinavirThe serum concentration of Quetiapine can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Indiplon.Investigational
IndoraminIndoramin may increase the antihypertensive activities of Quetiapine.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Quetiapine.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Quetiapine.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Quetiapine.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Quetiapine.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Quetiapine.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Quetiapine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Quetiapine.Approved
Iofetamine I-123Quetiapine may decrease the stimulatory activities of Iofetamine I-123.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Quetiapine.Approved, Investigational
IsavuconazoleThe serum concentration of Quetiapine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Quetiapine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Quetiapine can be increased when used in combination with Isocarboxazid.Approved
IsoetarineQuetiapine may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
IsomethepteneQuetiapine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoniazidThe metabolism of Quetiapine can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineQuetiapine may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Quetiapine.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Quetiapine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
ItraconazoleThe serum concentration of Quetiapine can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineQuetiapine may increase the QTc-prolonging activities of Ivabradine.Approved
IvacaftorThe serum concentration of Quetiapine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Quetiapine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Quetiapine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Quetiapine.Approved
LacidipineQuetiapine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Quetiapine.Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Quetiapine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Quetiapine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Quetiapine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levocetirizine.Approved
LevodopaQuetiapine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quetiapine.Approved
LevosalbutamolQuetiapine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Quetiapine.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Quetiapine is combined with Lidoflazine.Experimental
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Quetiapine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Quetiapine.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Quetiapine.Approved
LisdexamfetamineQuetiapine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Quetiapine.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Quetiapine.Experimental
LobeglitazoneThe metabolism of Quetiapine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Quetiapine can be increased when used in combination with Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Quetiapine is combined with Loperamide.Approved
LopinavirThe serum concentration of Quetiapine can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Quetiapine.Approved
LorcaserinThe metabolism of Quetiapine can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Quetiapine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Quetiapine.Approved
LovastatinThe metabolism of Quetiapine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Quetiapine.Approved
LuliconazoleThe serum concentration of Quetiapine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Quetiapine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lurasidone.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Quetiapine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Quetiapine can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Quetiapine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Quetiapine is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quetiapine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Quetiapine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Quetiapine is combined with Menthol.Approved
MephedroneQuetiapine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineQuetiapine may decrease the stimulatory activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Quetiapine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Quetiapine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Meptazinol.Experimental
MequitazineQuetiapine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Mesoridazine.Approved, Investigational
MetaraminolQuetiapine may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Quetiapine.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Quetiapine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineQuetiapine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Quetiapine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Quetiapine.Approved
MethotrimeprazineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineQuetiapine may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineQuetiapine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quetiapine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Quetiapine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenobarbital.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Quetiapine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Quetiapine.Approved, Investigational
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Quetiapine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Quetiapine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Quetiapine.Approved
MetyrosineQuetiapine may increase the sedative activities of Metyrosine.Approved
MibefradilThe risk or severity of hypotension can be increased when Quetiapine is combined with Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Quetiapine.Approved, Illicit
MidodrineQuetiapine may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineQuetiapine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Quetiapine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneQuetiapine may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Quetiapine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Quetiapine.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Quetiapine is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Quetiapine.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Quetiapine.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Quetiapine.Investigational
MirtazapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Quetiapine.Approved, Investigational
MitotaneThe serum concentration of Quetiapine can be decreased when it is combined with Mitotane.Approved
MMDAQuetiapine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Quetiapine can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Quetiapine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Quetiapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Quetiapine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Quetiapine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
NaftopidilThe risk or severity of hypotension can be increased when Quetiapine is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quetiapine.Approved
NaphazolineQuetiapine may decrease the vasoconstricting activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Quetiapine.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Quetiapine.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Quetiapine.Approved, Investigational
NefazodoneThe serum concentration of Quetiapine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Quetiapine can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Quetiapine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Quetiapine can be decreased when it is combined with Nevirapine.Approved
NicardipineNicardipine may increase the antihypertensive activities of Quetiapine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Quetiapine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Quetiapine.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Quetiapine.Approved
NiguldipineQuetiapine may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Quetiapine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Quetiapine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Quetiapine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Quetiapine.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Quetiapine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Quetiapine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Quetiapine.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Quetiapine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Quetiapine.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Quetiapine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nitrous oxide.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nordazepam.Approved
NorepinephrineQuetiapine may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineQuetiapine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Quetiapine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Normethadone.Approved, Illicit
NortriptylineQuetiapine may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinQuetiapine may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Quetiapine.Approved, Investigational
OctopamineQuetiapine may decrease the vasoconstricting activities of Octopamine.Experimental
OctreotideOctreotide may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Quetiapine.Approved
OlanzapineQuetiapine may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Quetiapine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Quetiapine.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Quetiapine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Quetiapine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Quetiapine.Approved
OpiumThe risk or severity of adverse effects can be increased when Quetiapine is combined with Opium.Approved, Illicit
OrciprenalineQuetiapine may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Quetiapine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Quetiapine can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of hypotension can be increased when Quetiapine is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Quetiapine.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quetiapine.Approved, Illicit, Investigational
OxyfedrineQuetiapine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineQuetiapine may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quetiapine.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Quetiapine.Approved, Vet Approved
PalbociclibThe serum concentration of Quetiapine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Quetiapine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Quetiapine can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Quetiapine.Approved, Investigational
ParaldehydeQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Quetiapine can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Quetiapine.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Quetiapine.Approved
Peginterferon alfa-2bThe serum concentration of Quetiapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Quetiapine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Penfluridol.Experimental
PentamidinePentamidine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quetiapine.Approved, Vet Approved
PentobarbitalThe serum concentration of Quetiapine can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Quetiapine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
PerazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Perazine.Approved, Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Quetiapine.Approved
PergolideQuetiapine may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Quetiapine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Quetiapine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Quetiapine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenazocine.Experimental
PhendimetrazineQuetiapine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Quetiapine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Quetiapine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenibut.Experimental
PhenobarbitalThe serum concentration of Quetiapine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Quetiapine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenoxyethanol.Approved
PhentermineQuetiapine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineQuetiapine may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineQuetiapine may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineQuetiapine may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Quetiapine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of QTc prolongation can be increased when Pimozide is combined with Quetiapine.Approved
PinaveriumThe risk or severity of hypotension can be increased when Quetiapine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Quetiapine.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Quetiapine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipotiazine.Approved, Investigational
PirbuterolQuetiapine may decrease the vasoconstricting activities of Pirbuterol.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Quetiapine.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Quetiapine.Approved, Investigational
PizotifenQuetiapine may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Quetiapine.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Quetiapine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
PramipexoleQuetiapine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Quetiapine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Quetiapine.Approved
PregabalinThe therapeutic efficacy of Quetiapine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolQuetiapine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Quetiapine is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Prilocaine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Quetiapine.Approved
PrimidoneThe serum concentration of Quetiapine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Procainamide is combined with Quetiapine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Quetiapine.Approved, Investigational
ProcaterolQuetiapine may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quetiapine.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
PropafenonePropafenone may increase the QTc-prolonging activities of Quetiapine.Approved
PropanididThe risk or severity of adverse effects can be increased when Quetiapine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Proparacaine.Approved, Vet Approved
PropericiazineQuetiapine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Quetiapine.Approved
PropiverineQuetiapine may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolPropofol may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Quetiapine.Approved, Investigational
ProtokylolQuetiapine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Quetiapine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Quetiapine is combined with PSD502.Investigational
PseudoephedrineQuetiapine may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Quazepam.Approved, Illicit
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Quetiapine.Approved, Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Quetiapine.Approved, Investigational
QuinidineThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Quetiapine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Quetiapine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Quinisocaine.Experimental
RacepinephrineQuetiapine may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Raclopride.Investigational
RactopamineQuetiapine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Quetiapine.Approved
RanolazineThe serum concentration of Quetiapine can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Quetiapine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quetiapine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Quetiapine.Approved, Investigational
ReproterolQuetiapine may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quetiapine.Approved, Investigational
RibociclibThe serum concentration of Quetiapine can be increased when it is combined with Ribociclib.Approved, Investigational
RifabutinThe serum concentration of Quetiapine can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Quetiapine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Quetiapine can be decreased when it is combined with Rifapentine.Approved, Investigational
RilmenidineQuetiapine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Quetiapine.Approved
RimiterolQuetiapine may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatThe risk or severity of adverse effects can be increased when Quetiapine is combined with Riociguat.Approved
RisperidoneQuetiapine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ritanserin.Investigational
RitobegronQuetiapine may decrease the stimulatory activities of Ritobegron.Investigational
RitodrineQuetiapine may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Quetiapine can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Quetiapine.Approved
RolapitantThe metabolism of Quetiapine can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Romifidine.Vet Approved
RopiniroleQuetiapine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Quetiapine.Approved, Investigational
RotigotineQuetiapine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Quetiapine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Quetiapine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Quetiapine.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Quetiapine.Approved
SaquinavirThe serum concentration of Quetiapine can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Quetiapine can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Quetiapine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Quetiapine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Quetiapine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Quetiapine is combined with Seletracetam.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Quetiapine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Quetiapine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Quetiapine.Approved
SiltuximabThe serum concentration of Quetiapine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Quetiapine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Quetiapine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
SolabegronQuetiapine may decrease the vasoconstricting activities of Solabegron.Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Quetiapine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Quetiapine.Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Quetiapine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Quetiapine.Approved
St. John's WortQuetiapine may increase the serotonergic activities of St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Quetiapine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Quetiapine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quetiapine.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Quetiapine.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Quetiapine.Approved, Investigational
SulpirideQuetiapine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Quetiapine.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
SuvorexantQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineQuetiapine may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Quetiapine.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Quetiapine.Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Quetiapine.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Quetiapine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tasimelteon.Approved, Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Quetiapine.Approved
TelaprevirThe serum concentration of Quetiapine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Quetiapine.Approved
TelithromycinThe serum concentration of Quetiapine can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Quetiapine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Quetiapine.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Quetiapine.Approved
TerbinafineThe metabolism of Quetiapine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Quetiapine.Approved
TerodilineThe risk or severity of hypotension can be increased when Quetiapine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Quetiapine.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Quetiapine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetrodotoxin.Investigational
TetryzolineQuetiapine may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Quetiapine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Thiopental.Approved, Vet Approved
ThioproperazineQuetiapine may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Quetiapine.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Quetiapine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Quetiapine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
TipranavirThe metabolism of Quetiapine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
TocilizumabThe serum concentration of Quetiapine can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Quetiapine.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Quetiapine.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Quetiapine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Quetiapine.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Quetiapine is combined with Tolfenamic Acid.Approved, Investigational
TolterodineTolterodine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
TopiramateThe metabolism of Quetiapine can be decreased when combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Quetiapine.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Quetiapine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Quetiapine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Quetiapine.Approved
TranilastThe risk or severity of hypotension can be increased when Quetiapine is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Quetiapine can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Quetiapine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Quetiapine.Approved, Investigational, Nutraceutical
TretoquinolQuetiapine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Quetiapine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Quetiapine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trichloroethylene.Approved
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Quetiapine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Quetiapine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Quetiapine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Quetiapine is combined with Trimethadione.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
TrimipramineQuetiapine may increase the antihypertensive activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Quetiapine.Investigational, Withdrawn
TulobuterolQuetiapine may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Quetiapine.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Quetiapine.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Quetiapine is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Quetiapine.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Quetiapine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Quetiapine.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Quetiapine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Veralipride.Experimental
VerapamilQuetiapine may increase the antihypertensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Quetiapine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Quetiapine.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Quetiapine.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Quetiapine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Quetiapine.Approved, Investigational
VoriconazoleThe serum concentration of Quetiapine can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vortioxetine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Quetiapine is combined with WIN 55212-2.Experimental
XamoterolQuetiapine may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Xylazine.Vet Approved
XylometazolineQuetiapine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Quetiapine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Quetiapine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Quetiapine.Approved, Investigational
ZolpidemQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Quetiapine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Quetiapine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference
US4879288
General References
  1. Dev V, Raniwalla J: Quetiapine: a review of its safety in the management of schizophrenia. Drug Saf. 2000 Oct;23(4):295-307. [PubMed:11051217]
  2. Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol. 2003 Fall;13(3):295-9. [PubMed:14642017]
  3. Tallerico T, Novak G, Liu IS, Ulpian C, Seeman P: Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. Brain Res Mol Brain Res. 2001 Mar 5;87(2):160-5. [PubMed:11245917]
  4. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577]
External Links
Human Metabolome Database
HMDB0005021
KEGG Compound
C07397
PubChem Compound
5002
PubChem Substance
46504800
ChemSpider
4827
BindingDB
50095890
ChEBI
8707
ChEMBL
CHEMBL716
Therapeutic Targets Database
DAP000001
PharmGKB
PA451201
IUPHAR
50
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Quetiapine
ATC Codes
N05AH04 — Quetiapine
AHFS Codes
  • 28:16.08.04 — Atypical Antipsychotics
FDA label
Download (273 KB)
MSDS
Download (57.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0TerminatedPreventionSocial Anxiety Disorder (SAD)1
0TerminatedTreatmentMethamphetamine Dependence1
1CompletedNot AvailableBipolar Disorder (BD)1
1CompletedNot AvailableSchizophrenic Disorders1
1CompletedBasic ScienceBipolar Disorder (BD) / Depressive Disorders / Psychotic Disorder NOS / Schizophrenic Disorders1
1CompletedBasic ScienceDepression1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentDyskinesia, Drug-Induced1
1CompletedTreatmentFasting State1
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
1CompletedTreatmentSchizophrenic Disorders1
1Unknown StatusTreatmentCocaine-Related Disorders1
1Unknown StatusTreatmentHealthy Volunteers1
1, 2RecruitingBasic ScienceSchizophrenic Disorders1
1, 2RecruitingTreatmentDisseminated Sclerosis1
1, 2TerminatedTreatmentDelirium1
2CompletedNot AvailableSpecific Phobias1
2CompletedBasic ScienceSmoking, Marijuana1
2CompletedTreatmentAlcohol Abuse / Alcohol Consumption / Alcohol Drinking / Alcohol Relapse Prevention / Alcoholism1
2CompletedTreatmentAlcohol Abuse / Alcoholism1
2CompletedTreatmentAlcohol Dependence1
2CompletedTreatmentAlcoholism1
2CompletedTreatmentAttention Deficit Disorder With Hyperactivity1
2CompletedTreatmentBorderline Personality Disorder (BPD)1
2CompletedTreatmentCannabis Dependence2
2CompletedTreatmentDepression, Bipolar1
2CompletedTreatmentMajor Depressive Disorder (MDD)2
2CompletedTreatmentObsessive Compulsive Disorder (OCD)1
2Not Yet RecruitingTreatmentSchizophrenic Disorders1
2RecruitingTreatmentMajor Depressive Disorder (MDD)1
2TerminatedTreatmentAnorexia Nervosa (AN)1
2TerminatedTreatmentBipolar Disorder (BD)1
2TerminatedTreatmentDepression in Patients With Bipolar Disorder1
2TerminatedTreatmentNicotine Dependence / Nicotine Use Disorder / Smoking / Tobacco Use Disorders1
2TerminatedTreatmentPostpartum Depressive Disorder1
2TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
2WithdrawnTreatmentMajor Depressive Disorder (MDD)1
2, 3CompletedTreatmentBipolar Disorder (BD)1
2, 3CompletedTreatmentBipolar II Disorder1
2, 3CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
2, 3CompletedTreatmentSleeplessness1
2, 3CompletedTreatmentSocial Anxiety Disorder (SAD)1
2, 3Not Yet RecruitingTreatmentDelirium1
2, 3TerminatedTreatmentSchizophrenic Disorders1
3CompletedNot AvailableBipolar Disorder (BD)1
3CompletedPreventionBipolar I Disorder1
3CompletedTreatmentAcute Bipolar Depression1
3CompletedTreatmentAlcohol Dependence / Bipolar I Disorder1
3CompletedTreatmentAlcoholism1
3CompletedTreatmentAlcoholism / Sleep Initiation and Maintenance Disorders1
3CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Vascular1
3CompletedTreatmentAnxiety Disorders1
3CompletedTreatmentAnxiety Disorders / Anxiety States / Feeling Anxious / Neuroses, Anxiety1
3CompletedTreatmentAnxiety Disorders / Bipolar Disorder (BD) / Feeling Anxious / Substance Use Disorder (SUD)1
3CompletedTreatmentBipolar Disorder (BD)6
3CompletedTreatmentBipolar Disorder (BD) / Depression, Bipolar2
3CompletedTreatmentBipolar Disorder (BD) / Depression / Depression, Bipolar1
3CompletedTreatmentBipolar Disorder (BD) / Elderly1
3CompletedTreatmentBipolar Disorder (BD) / Mania1
3CompletedTreatmentBipolar Disorder (BD) / Moods Disorders1
3CompletedTreatmentBipolar Disorder (BD) / Schizophrenic Disorders1
3CompletedTreatmentBipolar I Disorder1
3CompletedTreatmentBipolar I Disorder / Schizophrenic Disorders1
3CompletedTreatmentBipolar Youth Treated With Second-generation Antipsychotics1
3CompletedTreatmentBorderline Personality Disorder (BPD)2
3CompletedTreatmentChronic Schizophrenia1
3CompletedTreatmentCognition / Schizophrenic Disorders1
3CompletedTreatmentDelirium1
3CompletedTreatmentDepression, Bipolar3
3CompletedTreatmentDepression / Depressive Disorders / Major Depressive Disorder (MDD) / Moods Disorders / Psychiatric Disorder NOS1
3CompletedTreatmentDepression / Schizophrenic Disorders1
3CompletedTreatmentGeneralized Anxiety Disorder (GAD)3
3CompletedTreatmentMajor Depressive Disorder (MDD)8
3CompletedTreatmentMajor Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)1
3CompletedTreatmentMoods Disorders1
3CompletedTreatmentObsessive Compulsive Disorder (OCD)1
3CompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
3CompletedTreatmentPsychosis1
3CompletedTreatmentPsychotic Depression1
3CompletedTreatmentPsychotic Disorder NOS1
3CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
3CompletedTreatmentSchizophrenia and Schizoaffective Disorder1
3CompletedTreatmentSchizophrenic Disorders12
3CompletedTreatmentSleep1
3CompletedTreatmentSocial Anxiety Disorder (SAD)1
3CompletedTreatmentUnipolar Depression1
3RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3RecruitingTreatmentSchizophrenic Disorders1
3TerminatedTreatmentAcute Agitation / Dementias1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentBipolar Disorder (BD) / Psychotic Disorder NOS / Schizophrenic Disorders1
3TerminatedTreatmentDelirium1
3TerminatedTreatmentDepression With Prominent Agitation1
3TerminatedTreatmentGeneralized Anxiety Disorder (GAD) / Major Depressive Disorder (MDD)1
3TerminatedTreatmentMajor Depression With Psychotic Features1
3TerminatedTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders1
3TerminatedTreatmentSchizophrenic Disorders6
3TerminatedTreatmentSocial Anxiety Disorder (SAD)1
3Unknown StatusPreventionDelirium1
3Unknown StatusTreatmentBipolar Disorder (BD)1
3Unknown StatusTreatmentFeeling Anxious / Schizophrenic Disorders1
3Unknown StatusTreatmentPsychosis Nos/Other1
4Active Not RecruitingTreatmentBipolar Disorder (BD)1
4Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)1
4Active Not RecruitingTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1
4CompletedNot AvailableBipolar Disorder (BD)1
4CompletedNot AvailableDepression, Bipolar1
4CompletedNot AvailableMajor Depressive Disorder (MDD)1
4CompletedNot AvailableSchizophrenic Disorders2
4CompletedNot AvailableSchizophrenic Disorders / Substance Use Disorder (SUD)1
4CompletedDiagnosticSchizophrenic Disorders1
4CompletedOtherAlcohol Abuse / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Substance Abuse1
4CompletedOtherHealthy Volunteers1
4CompletedPreventionSchizophrenic Disorders1
4CompletedTreatmentAcute Agitation1
4CompletedTreatmentAcute Mania1
4CompletedTreatmentAcute Mania in Bipolar Disorder1
4CompletedTreatmentAlcohol Abuse/Dependence / Bipolar Disorder (BD)1
4CompletedTreatmentAlcohol Abuse / Bipolar Disorder (BD)1
4CompletedTreatmentAlcohol Dependence / Bipolar Disorder (BD)1
4CompletedTreatmentAlcoholism / Anxiety Disorders / Generalized Anxiety Disorder (GAD) / Obsessive-Compulsive Disorder (OCD) / Panic Disorders / Post-Traumatic Stress Disorder (PTSD)1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Alzheimer Type / Dementias / Senile Dementia, Alzheimer Type1
4CompletedTreatmentAnxiety Disorders1
4CompletedTreatmentBipolar Affective Psychosis / Bipolar Disorder (BD) / Mania / Manic Disorder / Manic syndromes1
4CompletedTreatmentBipolar Disorder (BD)4
4CompletedTreatmentBipolar Disorder (BD) / Cannabis-Related Disorder1
4CompletedTreatmentBipolar Disorder (BD) / Dependence, Cocaine1
4CompletedTreatmentBipolar Disorder (BD) / Mania1
4CompletedTreatmentBipolar I Disorder / Bipolar II Disorder1
4CompletedTreatmentBipolar II Disorder1
4CompletedTreatmentBipolar Spectrum Disorder1
4CompletedTreatmentCocaine-Related Disorders / Substance-Related Disorders1
4CompletedTreatmentCombat Disorders / Stress Disorders, Post-Traumatic1
4CompletedTreatmentDementias / Parkinson's Disease (PD)1
4CompletedTreatmentDepression1
4CompletedTreatmentDepression / Feeling Anxious1
4CompletedTreatmentDepression / Healthy Volunteers1
4CompletedTreatmentFibromyalgia3
4CompletedTreatmentHyperglycemias / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
4CompletedTreatmentMajor Depression With Comorbid Anxiety Symptoms1
4CompletedTreatmentMajor Depressive Disorder (MDD)3
4CompletedTreatmentMajor Depressive Disorder (MDD) / Menopausal Hot Flushes / Sleeplessness1
4CompletedTreatmentMood Disorders With Comorbid Anxiety Symptoms / Primary Anxiety Disorders1
4CompletedTreatmentObsessive Compulsive Disorder (OCD)2
4CompletedTreatmentPTSD1
4CompletedTreatmentPanic Disorders1
4CompletedTreatmentPsychomotor Agitation1
4CompletedTreatmentPsychotic Disorder NOS2
4CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders3
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders5
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Substance Abuse / Substance Dependence1
4CompletedTreatmentSchizophrenic Disorders17
4CompletedTreatmentSchizophrenic Disorders / Type 2 Diabetes Mellitus1
4CompletedTreatmentSocial Anxiety Disorder (SAD)1
4CompletedTreatmentSocial Phobia1
4RecruitingDiagnosticAsthma Bronchial / Asthma: [Nos] or [Attack] / Major Depressive Disorder (MDD)1
4RecruitingDiagnosticFirst Episode Psychosis / Schizoaffective Disorders / Schizophrenic Disorders1
4RecruitingTreatmentBipolar Disorder (BD)2
4RecruitingTreatmentBipolar Disorder (BD) / Substance Use Disorder (SUD)1
4RecruitingTreatmentDepressive Disorder, Treatment-Resistant1
4RecruitingTreatmentSchizophrenic Disorders1
4TerminatedNot AvailableHigh Risk MC4R Genotype / Low Risk MC4R Genotype / One Week or Less Antipsychotic Lifetime Exposure1
4TerminatedTreatmentAcute Bipolar Mania2
4TerminatedTreatmentBipolar Disorder (BD)2
4TerminatedTreatmentBipolar Disorder (BD) / Cognitive Impairments1
4TerminatedTreatmentComorbid Opiate Dependence in Remission / Generalized Anxiety Disorder (GAD) / Status Post Methadone-Maintenance Treatment1
4TerminatedTreatmentGeneralized Anxiety Disorder (GAD) / Major Depressive Disorder (MDD)1
4TerminatedTreatmentMajor Depressive Disorder With Psychotic Features1
4TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4TerminatedTreatmentSchizophrenic Disorders1
4Unknown StatusBasic ScienceDepression, Bipolar1
4Unknown StatusTreatmentAbnormal Mental State / Schizophrenic Disorders1
4Unknown StatusTreatmentAcute Schizophrenia1
4Unknown StatusTreatmentBipolar Disorder (BD)1
4Unknown StatusTreatmentBipolar, Mania / Seroquel / Utapine1
4Unknown StatusTreatmentBipolar / Schizophrenic Disorders1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentMental Health Disorder / Sleeplessness / Substance Use Disorder (SUD)1
4Unknown StatusTreatmentPsychosis1
4Unknown StatusTreatmentPsychosis / Schizophrenic Disorders1
4Unknown StatusTreatmentSchizophrenia or Schizoaffective Disorder1
4Unknown StatusTreatmentSchizophrenic Disorders1
4WithdrawnPreventionSchizophrenic Disorders1
4WithdrawnTreatmentAlzheimer's Disease (AD) / Behavioral Symptoms / Dementias1
4WithdrawnTreatmentDepression, Bipolar1
Not AvailableActive Not RecruitingNot AvailableSchizophrenic Disorders1
Not AvailableActive Not RecruitingTreatmentSchizophrenia Relapse1
Not AvailableCompletedNot AvailableBipolar Disorder (BD)1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Metabolic Syndromes / Psychotic Disorder NOS1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableDelirium / Dementias1
Not AvailableCompletedNot AvailableSchizophrenic Disorders1
Not AvailableCompletedDiagnosticBipolar Disorder (BD) / Mania1
Not AvailableCompletedDiagnosticSchizophrenic Disorders1
Not AvailableCompletedTreatmentAlzheimer's Disease (AD)1
Not AvailableCompletedTreatmentAnxiety Disorders / Dysthymic Disorder / Generalized Anxiety Disorder (GAD) / Major Depressive Disorder (MDD) / Panic Disorders / Post-Traumatic Stress Disorder (PTSD) / Social Anxiety Disorder (SAD)1
Not AvailableCompletedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedTreatmentBipolar Disorder (BD) / Dependence, Cocaine / Methamphetamine Dependence1
Not AvailableCompletedTreatmentBipolar I Disorder2
Not AvailableCompletedTreatmentCocaine Abuse / Dependence, Cocaine / Drug Abuse / Substance Abuse1
Not AvailableCompletedTreatmentFunctional Bowel Disorders1
Not AvailableCompletedTreatmentGeneralized Anxiety Disorder (GAD) / Major Depressive Disorder (MDD)1
Not AvailableCompletedTreatmentPhysiology, Ocular / Regional Blood Flow1
Not AvailableCompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
Not AvailableCompletedTreatmentPostpartum Depression1
Not AvailableCompletedTreatmentPrimary Insomnia1
Not AvailableCompletedTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders1
Not AvailableCompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
Not AvailableCompletedTreatmentSchizophrenic Disorders3
Not AvailableCompletedTreatmentTreatment for Bipolar I Disorder1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableNot Yet RecruitingBasic ScienceBipolar Disorder (BD) / Depression1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD) / Depression1
Not AvailableRecruitingNot AvailableMicrognathia / Schizophrenic Disorders1
Not AvailableRecruitingNot AvailableObesity, Morbid1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1
Not AvailableTerminatedTreatmentGeneralized Anxiety Disorder (GAD) / Seroquel XR1
Not AvailableUnknown StatusNot AvailableDissociative Disorders1
Not AvailableUnknown StatusEducational/Counseling/TrainingSmoking Behavior in Schizophrenia1
Not AvailableUnknown StatusPreventionPsychotic Disorder NOS1
Not AvailableUnknown StatusTreatmentAlzheimer's Disease (AD) / Sleeplessness1
Not AvailableUnknown StatusTreatmentAnorexia Nervosa (AN)1
Not AvailableUnknown StatusTreatmentBipolar Disorder (BD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Advanced Pharmaceutical Services Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • AstraZeneca Inc.
  • Atlantic Biologicals Corporation
  • Bryant Ranch Prepack
  • Cardinal Health
  • Comprehensive Consultant Services Inc.
  • Coupler Enterprises Inc.
  • Direct Dispensing Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Neuman Distributors Inc.
  • Norwich Pharmaceuticals Inc.
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Southwood Pharmaceuticals
  • Tya Pharmaceuticals
  • Vangard Labs Inc.
  • Wyeth Pharmaceuticals
Dosage forms
FormRouteStrength
Tablet, multilayer, extended releaseOral100 mg
Tablet, multilayer, extended releaseOral200 mg
Tablet, multilayer, extended releaseOral25 mg
Tablet, multilayer, extended releaseOral300 mg
TabletOral50 mg
TabletOral100 mg/1
TabletOral150 mg/1
TabletOral200 mg/1
TabletOral25 mg/1
TabletOral300 mg/1
TabletOral400 mg/1
TabletOral50 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coated, extended releaseOral150 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral300 mg/1
Tablet, film coated, extended releaseOral400 mg/1
Tablet, film coated, extended releaseOral50 mg/1
TabletOral300 mg
TabletOral100 mg
TabletOral200 mg
TabletOral25 mg
Kit
Tablet, extended releaseOral150 mg
Tablet, extended releaseOral150 mg/1
Tablet, extended releaseOral200 mg
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral300 mg/1
Tablet, extended releaseOral300 mg
Tablet, extended releaseOral400 mg/1
Tablet, extended releaseOral400 mg
Tablet, extended releaseOral50 mg/1
Tablet, extended releaseOral50 mg
TabletOral150 mg
Prices
Unit descriptionCostUnit
Seroquel 400 mg tablet16.71USD tablet
Seroquel xr 400 mg tablet14.82USD tablet
Seroquel 300 mg tablet14.21USD tablet
Seroquel xr 300 mg tablet12.61USD tablet
Seroquel 200 mg tablet10.84USD tablet
SEROquel XR 200 mg 24 Hour tablet10.0USD tablet
Seroquel xr 200 mg tablet9.62USD tablet
SEROquel XR 150 mg 24 Hour tablet9.09USD tablet
Seroquel xr 150 mg tablet8.74USD tablet
Seroquel 100 mg tablet5.75USD tablet
Seroquel 50 mg tablet5.5USD tablet
SEROquel XR 50 mg 24 Hour tablet5.06USD tablet
Seroquel xr 50 mg tablet4.87USD tablet
Seroquel 300 mg Tablet4.35USD tablet
Seroquel 25 mg tablet3.35USD tablet
Seroquel 200 mg Tablet2.98USD tablet
Apo-Quetiapine 300 mg Tablet2.44USD tablet
Co Quetiapine 300 mg Tablet2.44USD tablet
Jamp-Quetiapine 300 mg Tablet2.44USD tablet
Mylan-Quetiapine 300 mg Tablet2.44USD tablet
Novo-Quetiapine 300 mg Tablet2.44USD tablet
Pms-Quetiapine 300 mg Tablet2.44USD tablet
Ratio-Quetiapine 300 mg Tablet2.44USD tablet
Sandoz Quetiapine 300 mg Tablet2.44USD tablet
Apo-Quetiapine 200 mg Tablet1.67USD tablet
Co Quetiapine 200 mg Tablet1.67USD tablet
Jamp-Quetiapine 200 mg Tablet1.67USD tablet
Mylan-Quetiapine 200 mg Tablet1.67USD tablet
Novo-Quetiapine 200 mg Tablet1.67USD tablet
Pms-Quetiapine 200 mg Tablet1.67USD tablet
Ratio-Quetiapine 200 mg Tablet1.67USD tablet
Sandoz Quetiapine 200 mg Tablet1.67USD tablet
Seroquel 100 mg Tablet1.48USD tablet
Novo-Quetiapine 150 mg Tablet1.42USD tablet
Apo-Quetiapine 100 mg Tablet0.83USD tablet
Co Quetiapine 100 mg Tablet0.83USD tablet
Jamp-Quetiapine 100 mg Tablet0.83USD tablet
Mylan-Quetiapine 100 mg Tablet0.83USD tablet
Novo-Quetiapine 100 mg Tablet0.83USD tablet
Pms-Quetiapine 100 mg Tablet0.83USD tablet
Ratio-Quetiapine 100 mg Tablet0.83USD tablet
Sandoz Quetiapine 100 mg Tablet0.83USD tablet
Seroquel 25 mg Tablet0.56USD tablet
Apo-Quetiapine 25 mg Tablet0.31USD tablet
Co Quetiapine 25 mg Tablet0.31USD tablet
Jamp-Quetiapine 25 mg Tablet0.31USD tablet
Mylan-Quetiapine 25 mg Tablet0.31USD tablet
Novo-Quetiapine 25 mg Tablet0.31USD tablet
Pms-Quetiapine 25 mg Tablet0.31USD tablet
Ratio-Quetiapine 25 mg Tablet0.31USD tablet
Sandoz Quetiapine 25 mg Tablet0.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4879288No1994-09-262011-09-26Us
CA2251944No2007-04-102017-05-27Canada
US5948437Yes1997-11-282017-11-28Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityModerateNot Available
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0403 mg/mLALOGPS
logP2.93ALOGPS
logP2.81ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)15.12ChemAxon
pKa (Strongest Basic)7.06ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area48.3 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity114.09 m3·mol-1ChemAxon
Polarizability42.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9155
Blood Brain Barrier+0.9906
Caco-2 permeable-0.6037
P-glycoprotein substrateSubstrate0.8424
P-glycoprotein inhibitor IInhibitor0.9117
P-glycoprotein inhibitor IIInhibitor0.9325
Renal organic cation transporterInhibitor0.5554
CYP450 2C9 substrateNon-substrate0.6438
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6049
CYP450 1A2 substrateInhibitor0.5744
CYP450 2C9 inhibitorNon-inhibitor0.6305
CYP450 2D6 inhibitorInhibitor0.588
CYP450 2C19 inhibitorNon-inhibitor0.7033
CYP450 3A4 inhibitorInhibitor0.7961
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5375
Ames testNon AMES toxic0.7479
CarcinogenicityNon-carcinogens0.869
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6537 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9483
hERG inhibition (predictor II)Inhibitor0.8684
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - DI-ESI-qTof , NegativeLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0089000000-b7b1c7d0bf6bb604c5cb
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0uk9-1390000000-ce855b6e08dee583681b

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzothiazepines. These are compounds containing a dibenzothiazepine moiety, which consists of two benzene connected by a thiazepine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazepines
Sub Class
Dibenzothiazepines
Direct Parent
Dibenzothiazepines
Alternative Parents
Diarylthioethers / N-alkylpiperazines / Imidolactams / Benzenoids / Trialkylamines / Propargyl-type 1,3-dipolar organic compounds / Dialkyl ethers / Carboxamidines / Azacyclic compounds / Primary alcohols
show 2 more
Substituents
Dibenzothiazepine / Diarylthioether / Aryl thioether / N-alkylpiperazine / 1,4-diazinane / Piperazine / Benzenoid / Imidolactam / Tertiary amine / Tertiary aliphatic amine
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, N-alkylpiperazine, dibenzothiazepine (CHEBI:8707)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Goldstein JM: Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc). 1999 Mar;35(3):193-210. [PubMed:12973385]
  2. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ: A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother. 2007 Jun;8(9):1211-9. [PubMed:17563257]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  4. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR: Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-8. [PubMed:16038601]
  5. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
2. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P: A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000 Jun;57(6):553-9. [PubMed:10839333]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706]
  4. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Ichikawa J, Li Z, Dai J, Meltzer HY: Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002 Nov 29;956(2):349-57. [PubMed:12445705]
  2. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ: A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother. 2007 Jun;8(9):1211-9. [PubMed:17563257]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  4. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396]
  5. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that trig...
Gene Name
HTR1E
Uniprot ID
P28566
Uniprot Name
5-hydroxytryptamine receptor 1E
Molecular Weight
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
11. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
12. D(1B) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
13. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
14. D(4) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
15. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577]
  2. DeVane CL, Nemeroff CB: Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509-22. [PubMed:11510628]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686]

Drug created on June 13, 2005 07:24 / Updated on July 20, 2018 19:32